Experience in the Use of the β-Interferon-1a Biosimilars CinnoVex and Genfaxon-44 at the Moscow City Multiple Sclerosis Center

摘要

Objective: To study the efficacy and tolerability of the generic drugs (β-interferon-1a biosimilars) CinnoVex for i.m. administration and Genfaxon-44 for s.c. administration in multiple sclerosis (MS). Materials and methods: A total of 100 MS patients were treated with CinnoVex and 104 patients were treated with Genfaxon, in each case for one year. Status was assessed clinically using several scales, as well as by MRI scanning. Results and conclusions: High frequencies of treatment withdrawal due to lack of clinical efficacy and intolerability were noted. Positive effects in relation to stabilizing the course of MS were seen only in patients who had not previously been treated with MS disease-modifying drugs (DMD). Final resolution of the question of the equivalence of the original and "generic" drugs requires double-blind studies.